MRI Predictors of Response to Tumor Treating Fields

Status unconfirmed

Conditions studied: Glioblastoma Multiforme

In brief

Patients with glioblastoma, an aggressive brain tumor, are recommended to undergo treatment with tumor treating fields using the Optune device as part of standard of care therapy. While undergoing treatment, patients are monitored regularly with brain MRI scans to look for tumor progression, but there are currently no means to predict which, or when, patients will progress. The purpose of the current study is to prospectively analyze these MRI scans to look for subtle imaging markers that can predict for future brain tumor progression while undergoing tumor treating field therapy.

Key facts

Study ID

NCT03642080

Run by

New York Presbyterian Brooklyn Methodist Hospital

People needed

48

Starts

2018-12-01

Expected to finish

2023-12-31

Last updated by the study team

2018-12-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients age 18 or older with newly diagnosed WHO grade IV glioblastoma or patients with recurrent glioblastoma not previously treated with TTFields.
• Patients may have undergone surgical resection or biopsy.
• Residual tumor, absence of treatment with temozolomide or radiation therapy will not be an exclusion criteria for the study.

You may not qualify if…

• Patients previously treated with TTFields will not be included in the study.
• Patients will also be excluded if they are undergoing active treatment with systemic agents, including bevacizumab, during treatment with TTFields.

Where it is running

• New York Presbyterian - Brooklyn Methodist Hospital — Brooklyn, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.